Choice of empirical therapy and prophylaxis

Hematology Journal

Volumn 5, Issue SUPPL. 3, 2004, Pages

  Del Favero, Albano ^a   Bucaneve, Giampaulo ^a   Furno, Paolo ^a  

^a POLICLINICO MONTELUCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFIXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TICARCILLIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG EFFICACY; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEVER; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; INFECTION CONTROL; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 4043062140     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200423     Document Type: Article

References (17)

1. Murphy M, Brown AE, Sepkowitz A et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer-is it justified? Clin Infect Dis 1997; 25: 346-347.
2. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-1187.
3. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer: a trial of oral penicillin V or placebo combined with pefloxacin. JAMA 1994; 272: 1183-1189.
4. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
5. Pizzo PA. Managment of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332.
6. Wade JC. Antibiotic therapy for the febrine granulocytopenic cancer patient: combination therapy vs Monotherapy. J Infect Dis 1989; 11: 1572-1581.
7. Pizzo PA, Hathorn JW, Hiemens J et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-558.
8. De Pauw BE, Deresinski SC, Feld R et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med 1994; 120: 834-844.
9. Cometta A, Calandra T, Gaya H et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
10. Del Favero A, Menichetti F, Martino P et al. A multi-center, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-301.
11. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-242.
12. Johnson MP, Ramphal R. Β-Lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990; 162: 981-983.
13. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.
14. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999; 29: 503-507.
15. Freifeld A, Marchigiani A, Wlsh T et al. A double-blind comparison of emprical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305-311.
16. Kern WV, Cometta A, DeBock R et al. Oral versus intrvenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312-318.
17. Shenep JL, Flynn PM, Baker DK et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 2001; 32: 36-43.